Navigation Links
Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market
Date:5/17/2011

PISGAH FOREST, N.C., May 17, 2011 /PRNewswire/ -- Responding quickly to the FDA's proclaimed new limits on acetaminophen in prescription painkiller combination products, Pisgah Laboratories, Inc., http://www.pisgahlabs.com, files a patent application on abuse deterrent features for opioid drug products. Filed with the US Patent & Trademark Office (http://www.uspto.gov), this new patent application is the eighteenth filing for Pisgah and represents a substantial R&D effort directed toward a broad-based platform technology addressing the horrific effects of drug abuse.

Drug abuse has crept into every facet of global society with untold human costs and is an incalculable financial drain on a nation. Governmental efforts to stem drug abuse are essentially ineffective and recidivism high. At a time when the United States needs a "break," drug abuse continues to squander human talent and resources, but Pisgah Labs' scientists remain focused on reducing abuse of popular prescription drugs. Indeed, nearly one-hundred and forty million prescriptions are written annually for hydrocodone in combination with acetaminophen (APAP). Many of these products, containing APAP in large dosage amounts, are purported to cause liver toxicity and the FDA has established new limits for the amount of APAP allowed. The new rulings come at a favorable time in Pisgah's product development cycle as they develop abuse deterrent hydrocodone / acetaminophen products.

Unlike older attempts to manipulate the abuse potential by formulation, Pisgah has scientifically addressed the abuse potential at the active ingredient level. Pisgah has identified new salt forms of hydrocodone which significantly improve its performance features compared with hydrocodone bitartrate currently used in the industry. Indeed, Pisgah has avoided the pitfalls often found in commercializing pro-drugs or relying solely on formulation techniques to solve complex problems. Pisgah has identified salt forms of nearly all the commercial opiates used in prescription pain medications which will impart abuse deterrent features. The drug abuser will find it more difficult to separate the active ingredient from the dosage form, and the active ingredient will be far less soluble in the abuse-route mucosa (nasal, vaginal, rectal). However, it is important to note, the drug will perform properly when used as intended by oral administration -- and when taken as prescribed, the release of the drug is not accelerated by drinking alcohol.

As for an integrated commercial offering covering other popular pain medications, Pisgah is continuing their research efforts while aggressively pursuing a development program for hydrocodone / acetaminophen combination products. In laboratory testing, Pisgah has shown they can "adjust" the properties of the new salts to yield immediate or controlled release versions. In general, the drug development pathway can be quite tortuous with unexpected events occurring, such as the FDA's mandate to reduce acetaminophen levels in products like Pisgah is developing. Fortunately, Pisgah sees this change more as an opportunity than a difficulty. As Pisgah's President, Bill Bristol, commented, "The mandated lower levels of acetaminophen allows for our technology's benefits to shine and not to be eclipsed by the health issues raised by higher levels of acetaminophen in combination products."

With eighteen patent applications and more on the way, Pisgah's intellectual property stable continues to grow, and is applicable to dozens of abused prescription drugs. Pisgah's technology provides an integrated solution to three principal concerns within the medical community: 1) improving patient care; 2) reducing medical practice liability; and 3) reducing barriers for treating pain. Pisgah anticipates its new products will be well-received by all stakeholders interested in reducing the nation's drug abuse epidemic.            

For more information or to discuss licensing opportunities, please contact:

Todd Stamps
Business and Market Development
803-212-8224

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Pisgah Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NEURO-BIOTECH CORPORATION: Updates and latest developments
2. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Comply with Latest FDA Expectations for Validation and Part 11
3. Micro rheometer is latest Lab On a Chip device
4. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
5. CBR Pharma Insights' Latest Report, The New Era of Healthcare Reform - Supporting Revenue Growth through Understanding & Adaptation
6. Latest breakthroughs in technology expand options for diagnosing and treating disease
7. Healthcare Data Solutions Announces Latest Database, PrescriberPRO@Home.
8. The Latest in Digital USB Microscopes from Cole-Parmer
9. New STR Systems from Promega Comply with Latest DNA Database Standards
10. LS9 Secures $25 Million in Latest Round of Funding
11. World Renowned Scientists Gather to Share Latest Information on Answer to Wildlife Reproductive Fertility Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients ... asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new ... of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies ...
(Date:5/19/2016)... , ... May 19, 2016 , ... Anton Paar USA, ... square foot office building is complete. The new structure adds a third office building ... Anton Paar USA purchased 2.4 acres of land, along with office space adjacent ...
(Date:5/19/2016)... - I dati saranno presentati nel ... ° Congresso della Società Americana di Oncologia ... conclusioni dello studio indicano un tasso di risposta del 56% ... presenta una d urata della risposta (Duration Of Response, ... dei pazienti ha riscontrato un beneficio clinico.      ...
(Date:5/18/2016)... Fort Washington, PA (PRWEB) , ... May 18, ... ... and at least 1,200 hospitalizations are a direct result of asthma complications.* Costing ... health challenge across the country. , “For too many, the ...
Breaking Biology Technology:
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
Breaking Biology News(10 mins):